There continues to be evidence that AMD is not one disease but a collection of them, some of which are based on genetics. A recent article says “APL-2, a complement C3 inhibitor, has met its primary endpoint in its phase 2 clinical trial, reducing the rate of geographic atrophy (GA) associated with age-related macular degeneration (AMD).” We have reason to hope for…
What’s the difference between ‘low vision’, ‘legally blind’, ‘visually impaired’? Sue helps you to…
Start at the beginning…
Are these pages the first ones that you’ve read in Sue’s Journal of her Journey with AMD? We recommend that you click here to read In the Beginning.